Acute events in hospitalized patients with sickle cell anemia before and after the use of hydroxyurea

Olinda Maria Rodrigues de Araújo, Maria Lúcia Ivo, Albert Schiaveto de Souza, Ana Tereza Gomes Guerrero, Alexandra Maria Almeida Carvalho, Francine Ramos de Miranda, Maria Angélica Marcheti, Abílio Torres dos Santos Neto, Elaine Silva de Pádua Melo, Isabelle Campos de Azevedo, Magda Maria Barbosa da Silva, Ricardina Oliveira da Silva (+1 others)
2016 International Archives of Medicine  
Objective: To estimate the occurrence of acute events in hospitalized patients with sickle cell anemia (SCA) before and after the use of hydroxyurea (HU). Method: The study has a quantitative approach, of analytical cohort type developed in two public referral hospitals in the Midwest region of Brazil Results: The sample had 32 medical records of hospitalized patients diagnosed with SCA who used HU. The mean age of the participants was 25.65±11.92; the average time of drug exposure was 6.0±2.8
more » ... posure was 6.0±2.8 years; the average initial dose was 17.00±5.3mg/kg/day and final dose of 22.10±5.3 mg/kg/day. After using HU, the fetal hemoglobin ranged from 8.41±0.95 to 14.44±13.7% (p<0.001). There was a reduction of the average leucocyte, absolute neutrophil, acute events, total infections and blood transfusions. Conclusion: The effects of HU exposure caused an increase in fetal hemoglobin level, decreasing leukocyte, absolute neutrophils and acute events, transfusions and hospitalizations by the use of non-opioid.
doi:10.3823/2220 fatcat:u2rrbhv33bgb3lrv5orrrpltka